RBC Capital reiterated coverage on Global Blood Therapeutics with a new price target

11/5/21 8:44:35 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

RBC Capital reiterated coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $64.00 from $66.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GBT

Date	Price Target	Rating	Analyst
8/8/2022		Outperform → Mkt Perform	William Blair
8/8/2022	$40.00 → $72.00	Hold → Buy	Canaccord Genuity
3/28/2022	$138.00 → $71.00	Outperform	Wedbush
2/28/2022	$28.00 → $31.00	Equal-Weight	Morgan Stanley
2/24/2022	$92.00 → $86.00	Outperform	Oppenheimer
12/21/2021	$56.00 → $53.00	Outperform	SVB Leerink
12/14/2021	$54.00 → $56.00	Outperform	SVB Leerink
12/7/2021		Market Perform → Outperform	William Blair